Table 1.
Comparison between APC and control groups
| APC (n = 24) | Control (n = 28) | Total (n = 52) | P value | |
|---|---|---|---|---|
| Gender (%) | .061 | |||
| Male | 13 (54.2) | 22 (78.6) | 35 (67.3) | |
| Female | 11 (45.8) | 6 (21.4) | 17 (32.7) | |
| Age (years ± SD) | 57 ± 13 | 62 ± 11 | 60 ± 12 | .159 |
| Hemoglobin (g/dL ± SD) | 7.3 ± 2.7 | 8.2 ± 2.3 | 7.8 ± 2.5 | .177 |
| Clinical presentation (%) | .516 | |||
| Hematemesis | 9 (37.5) | 13 (46.4) | 22 (42.3) | |
| Others | 15 (62.5) | 15 (53.6) | 30 (57.7) | |
| ECOG | .376 | |||
| I (good PS) | 18 (75) | 17 (60.7) | 35 (67.3) | |
| II (poor PS) | 6 (25) | 11 (39.3) | 17 (32.7) | |
| Bleeding site (%) | .108 | |||
| Duodenum | 7 (29.2) | 3 (10.7) | 10 (19.2) | |
| Esophagus | 3 (12.5) | 9 (32.1) | 12 (23.1) | |
| Stomach | 14 (58.3) | 16 (57.1) | 30 (57.7) | |
| Active bleeding (%) | 15 (62.5) | 4 (14.3) | 19 (36.5) | < .001 |
| Additional treatment (%) | 9 (37.5) | 8 (28.6) | 17 (32.7) | .494 |
| Re-bleeding (%) | 8 (33.3) | 4 (14.3) | 12 (23.1) | .104 |
| Mortality (%) | 5 (20.8) | 12 (42.9) | 17 (32.7) | .091 |
APC: argon plasma coagulation; ECOG: Eastern Cooperative Oncology Group performance status (Group I: good performance status (ECOG 0–2); Group II: poor performance status (ECOG 3–4)); PS: performance status; SD: standard deviation.